| Product Name | $:$ Ralaniten |
| :--- | :--- |
| Cat. No. | $: \mathrm{PC}-60529$ |
| CAS No. | $: 1203490-23-6$ |
| Molecular Formula $: \mathrm{C}_{21} \mathrm{H}_{27} \mathrm{ClO}_{5}$ |  |
| Molecular Weight | $: 394.89$ |
| Target | $:$ Androgen Receptor (AR) |
| Solubility | $: 10 \mathrm{mM}$ in DMSO |

## Biological Activity

Ralaniten (EPI-002) is a novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.
AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs.

## References

Antonarakis ES, et al. Oncologist. 2016 Dec;21(12):1427-1435.

